NASDAQ$SANA
Sana Biotechnology Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Sana Biotechnology reported financial results for Q4 2021 and provided business updates.
Sana Biotechnology reported a cash position of $746.9 million, research and development expenses of $108.5 million, and a net loss of $110.7 million for the fourth quarter of 2021. The company is progressing towards clinical trials for its multiple platforms and expects to file INDs for SC291 and SG295 in 2022.
- Cash, cash equivalents, and marketable securities totaled $746.9 million.
- Research and development expenses were $108.5 million.
- Net loss was $110.7 million, or $0.60 per share.
- The company expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana Biotechnology plans to present data at multiple scientific conferences in 2022 and expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022.
Tailwinds
- Continued progress in building Sana’s hypoimmune ex vivo platform
- Progressed Sana’s hypoimmune allogeneic CD19-targeted CAR T program, SC291; IND expected as early as this year
- Progressed Sana’s in vivo CAR T program, SG295, utilizing a CD8-targeted fusosome to deliver a CD19-targeted CAR; IND expected as early as this year
- Expanded Sana’s CAR T capability to potentially develop best-in-class, broadly accessible CAR T cell therapies
- Progressed Sana’s stem cell-derived pancreatic beta cell program, SC451, with potential to treat type 1 diabetes
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro